LXEO
NASDAQLexeo Therapeutics Inc.
Price$2.75+0.12 (+4.56%)
01:30 PM07:45 PM
News · 26 weeks53+1100%
2026-04-192026-10-11
Mix2590d
- Other14(56%)
- Insider7(28%)
- SEC Filings4(16%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.SCHEDULE 13G - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- PRLexeo Therapeutics to Participate in the Chardan Healthcare ConferenceNEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at Chardan’s 10th Annual Healthcare Conference on October 20, 2026 at 9:30am ET. The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation. About Lexeo TherapeuticsLexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing
- PRLexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control cohort from UNIFAI natural history study Presentation will include new mFARS subscore analyses providing additional insight into neurologic outcomes following LX2006 treatment NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, announced today its abstract has been accepted to be presented at the International Congress of Parkinson’s Disease and Movement Disorders 20
- SECLexeo Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Tamayo Louis Edward4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERChief Operating Officer Otero Jose Manuel was granted 2,110 shares, increasing direct ownership by 2% to 138,288 units (SEC Form 4)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERChief Medical Officer Bhalla Narinder Pal was granted 2,714 shares, increasing direct ownership by 3% to 84,908 units (SEC Form 4)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERChief Executive Officer Townsend Richard Nolan was granted 2,306 shares, increasing direct ownership by 0.62% to 376,778 units (SEC Form 4)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- PRApertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich AtaxiaNEW YORK, Sept. 23, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, access to TfR1 CapX™ for a program designed to treat Friedreich ataxia. Apertura's TfR1 CapX is an intravenously delivered AAV capsid designed to target human transferrin receptor 1 (hTfR1) and cross the blood-brain barrier. "As an intravenously delivered capsid designed to cross the blood-brain barrier, TfR1 CapX holds th
- PRLexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic ForumNEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET. The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation. About Lexeo TherapeuticsLexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By adva
- SECLexeo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
- PRLexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich AtaxiaAcquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace frataxin in the brain Collaborations launched to evaluate gene therapy sequential dosing following treatment with LX2006 and explore cerebellar targeting to optimize outcomes in FA associated neurological disease SUNRISE-FA 2 pivotal study continues enrollment and remains the company’s top priority development program; topline data on track for 2H 2027 Disciplined capital allocation supports these strategic initiatives while maintaining cash runway into 2028 Company to host webcast today at 8:00 AM ET NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO),
- PRLexeo Therapeutics to Participate in Upcoming Investor Conferences in SeptemberNEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO) a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in September: Cantor Global Healthcare Conference 2026. Fireside chat on Wednesday, September 9, 2026 at 2:10 p.m. ET in New York, NY. Baird 2026 Global Healthcare Conference. Fireside chat on Tuesday, September 15, 2026 at 11:25 a.m. ET in New York, NY. The events will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcasts w
- INSIDERChief Financial Officer Tamayo Louis Edward sold $20,203 worth of shares (4,117 units at $4.91), decreasing direct ownership by 4% to 92,907 units (SEC Form 4) (tax withholding)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERChief Executive Officer Townsend Richard Nolan sold $16,562 worth of shares (3,345 units at $4.95), decreasing direct ownership by 0.89% to 374,472 units (SEC Form 4) (withholding tax)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERChief Operating Officer Otero Jose Manuel sold $6,464 worth of shares (1,304 units at $4.96), decreasing direct ownership by 0.95% to 136,178 units (SEC Form 4) (for tax liability)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.SCHEDULE 13G - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- SECSEC Form 10-Q filed by Lexeo Therapeutics Inc.10-Q - Lexeo Therapeutics, Inc. (0001907108) (Filer)
- SECLexeo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
- PRLexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational HighlightsFinalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled into pivotal study in June; site activation efforts ongoing CLARITY-FA enrollment continues to advance, supporting identification of eligible participants for SUNRISE-FA 2 FDA granted RMAT designation for LX2020 based on recent interim clinical data in PKP2-ACM Cash, cash equivalents and investments of $234.2 million expected to provide operational runway into 2028 NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genet
- SECSEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.SCHEDULE 13G - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- PRLexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic CardiomyopathyRMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM LX2020 now holds RMAT, Orphan Drug and Fast Track designations by the FDA NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to LX2020, the Company’s investigational AAV-based gene therapy candidate for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). RMAT
LXEO FAQ
6 questionsWhere does LXEO stock trade?
Lexeo Therapeutics Inc. (LXEO) is listed on NASDAQ.What sector and industry is LXEO in?
Lexeo Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Lexeo Therapeutics Inc. go public?
Lexeo Therapeutics Inc. (LXEO) completed its IPO in 2023.What are analysts saying about LXEO?
Lexeo Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Strong Buy with a $2500.00 price target on 2025-12-18. Recent price targets range from $1900.00 to $3000.00.What companies are similar to LXEO?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare LXEO side-by-side with any of them on Quantisnow.How can I track LXEO on Quantisnow?
Quantisnow aggregates Lexeo Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LXEO to receive live email and push alerts on every new disclosure.